Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Intervention never conducted
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centers for Medicare and Medicaid Services | FED |
| General Services Administration (GSA) | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Inappropriate prescribing exposes patients to health risks and results in wasteful public expenditures. This study will evaluate an approach to fighting abusive prescription: sending letters to suspected potentially inappropriate prescribers warning them that they are outliers compared to their peers and have been flagged for review. The study will target high prescribers of opioids in the Schedule II controlled substances class. Two types of letters will be tested: one focusing on the health consequences of inappropriate prescribing for patients, and the other focusing on the consequences for prescribers including e.g. potential administrative actions. Using claims data, the investigators will assess the effect of the letters on prescribing of opioids, receipt of opioids by patients, substitution behavior by prescribers and patients, and health outcomes of patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | The control arm will not receive any communications as a result of this study. | |
| Patient Consequences | Experimental | The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients. |
|
| Prescriber Consequences | Experimental | The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient Consequences Letter | Other | This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Morphine Milligrams Equivalent (MME) | 9 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adam Sacarny, PhD | Columbia University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Prescriber Consequences Letter | Other | This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison. |
|